Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2008

View Archived Issues

Meritage acquires Verus's pediatric gastrointestinal development program

Phase II data reported for ixabepilone in renal cell carcinoma, prostate cancer, pediatric tumors

TSU-68 active in phase I/II hepatocellular carcinoma trial

Medicis is to acquire LipoSonix for USD 150 million

Targeting the SDF-1/CXCR4 axis may prolong allograft survival in islet cell transplantation

XL-765 well tolerated thus far in phase I study in solid tumor patients

Phase I study assesses intermittent and continuous XL-184 dosing in advanced cancer

Novel soluble guanylate cyclase activators for cardiovascular disorders claimed in Bayer patent

Biotie's VAP-1 antibody program to proceed to clinical studies in RA and psoriasis

Tranzyme reports successful completion of phase I trial of TZP-102 in gastroparesis

Alnylam and Kyowa Hakko form alliance for ALN-RSV01 in Asia

SUVN-502 enters phase I trials for Alzheimer's disease

Eurand receives approvable letter for EUR-1008

Inotek begins a phase I trial of INO-8875 for the treatment of glaucoma

Axelar initiates phase I/II trial of AXL-1717 in cancer patients

Tracon doses first cancer patient in phase I oral TRC-102 trial

Algeta initiates phase III clinical study of Alpharadin in advanced prostate cancer

Intercell submits application to register Japanese encephalitis vaccine in Canada

OSI initiates clinical development program for PSN-602 in obesity

Aradigm starts phase II inhaled liposomal ciprofloxacin study in bronchiectasis

Allergan patents novel prostanoid EP2 agonist prodrugs

Merck submits application in E.U. to extend use of Erbitux

Ark Therapeutics' EG-011 demonstrates ability to grow new blood vessels

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...